Fiche centre
Virginia Cancer Specialists
Fairfax — United States
Essais liés8clinical trials
VilleFairfaxlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06349408
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| INBRX-106 - Hexavalent OX40 agonist antibody | Cancer | Phase 1/2 | NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | RECRUITING |
| VS-7375 | Cancer | Phase 2 | NCT07659782 | TARGET-D 202 — A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer | RECRUITING |
| VS-7375 | Cancer | Phase 2 | NCT07659795 | TARGET-D 203 — A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | RECRUITING |
| Pasritamig | Cancer | Phase 3 | NCT07164443 | KLK2-comPAS — A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING |
| IBI3001 | Cancer | Phase 1 | NCT06349408 | IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors | RECRUITING |
| cemacabtagene ansegedleucel | SEP | Phase 2 | NCT06500273 | ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | RECRUITING |
| ZL-1310 | Cancer | Phase 3 | NCT07218146 | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | RECRUITING |
| Amivantamab | Cancer | Phase 3 | NCT04538664 | PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | ACTIVE_NOT_RECRUITING |